Becker's Hospital Review3h
FDA approves injectable version of popular cancer drug
The FDA approved a subcutaneous injection version of Bristol Myers Squibb nivolumab and hyaluronidase-nvhy for the treatment of several cancers including melanoma, non-small cell lung cancer and renal ...
Contract Pharma8h
FDA Approves BMS’ Opdivo Qvantig with Halozyme’s ENHANZE Technology
Becomes the first subcutaneously administered PD-1 inhibitor.
Targeted Oncology3d
FDA Approves Subcutaneous Nivolumab Across Existing Solid Tumor Indications
On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...
Pharmabiz18h
US FDA approves Opdivo Qvantig injection, for subcutaneous use in most previously approved adult, solid tumour Opdivo indications
US FDA approves Opdivo Qvantig injection, for subcutaneous use in most previously approved adult, solid tumour Opdivo indications: Princeton, New Jersey Monday, December 30, 2024, ...
Too Old to Operate20d
Survival Up With Nivolumab + Ipilimumab Versus Chemo for Metastatic CRC
For patients with microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer ...
Targeted Oncology3d
Top 10 Genitourinary Cancer Advances in 2024
In January 2024, the FDA approved erdafitinib (Balversa) for adult patients with locally advanced or metastatic urothelial ...
Renal & Urology News28d
Adding Nivolumab to Tivozanib Provides No Benefit in RCC After Prior ICI
Results from the phase 3 TiNivo-2 trial suggest that immune checkpoint inhibitor rechallenge should generally be discouraged ...
manilatimes9h
CARsgen Announces Positive Topline Results from China GC/GEJ Pivotal Phase II Clinical Trial of Claudin18.2 CAR-T (Satri-cel)
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the ...